Design of a dual-signaling sensing system for fluorescent ratiometric detection of Al3+ ion based on the inner-filter effect.

A dual-signal sensing system based on the inner-filter effect (IFE) was demonstrated, in which the combination of two signaling mechanisms allows metal binding to turn on two fluorescence emission bands, independently. A proof-of-concept fluorescent ratiometric assay for Al(3+) in pure aqueous solution is presented. The proposed assay is based on the Al(3+)-induced color and fluorescence changes of Alizarin red S (ARS) and IFE between ARS and meso-tetra(N-methyl-4-pyridyl)porphine tetratosylate salt (TMPyP). In the absence of Al(3+), the absorption spectrum of the ARS in 0.2 M HAc-NaAc buffer (pH 5.5) has a strong peak at 420 nm, significantly overlapping with the excitation of TMPyP. ARS is expected to be capable of functioning as a powerful absorber to tune the emission of TMPyP on account of the spectral overlap. Binding of Al(3+) with ARS forms a fluorometric ARS/Al(3+) complex and shifts the maximum absorbance from 420 nm to 480 nm, which overlaps negligibly with the excitation of TMPyP and turns on the proper emission spectrum for TMPyP. Under the optimum conditions, The fluorescence intensity ratio, F(585)/F(651), responds to Al(3+) over a dynamic range of 0.1-1.5 µM, with a limit of detection of 40 nM, where F(585) and F(651) are the fluorescence intensity at 585 nm and 651 nm in the absence or presence of Al(3+), respectively. Further application in Al(3+)-spiked water samples suggested a recovery between 95 and 108%. The fluorescence response is highly selective for Al(3+) over other metal ions with the addition of thiourea as the masking agent.

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.

The TNF antagonists adalimumab, infliximab, and etanercept are effective treatments for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, but only adalimumab and infliximab have been found to be efficacious in Crohn's disease. The present studies evaluated the TNF-binding and complement-activating properties of adalimumab, infliximab, and etanercept to determine whether these properties may explain differences in their clinical efficacy profiles. Association and dissociation rates of binding to soluble TNF were measured by surface plasmon resonance, and were found to be similar for adalimumab, infliximab, and etanercept, as were their calculated binding affinities. Avidity of binding to soluble TNF, measured by KinExA technology, was 10- to 20-fold greater for soluble etanercept (K(D)=0.4 picomolars [pM]) than for soluble adalimumab or infliximab (K(D)=8.6 and 4.2 pM, respectively). (125)I-adalimumab, -infliximab, and -etanercept bound to membrane TNF (mTNF) on mTNF-transfected cells with similar affinities (K(D)=483, 468, and 445 pM, respectively) that were each lower than for soluble TNF. Complement-dependent cytotoxicity (CDC) was induced in mTNF-transfected cells by adalimumab and infliximab, but was not induced in activated normal human PBMC by any of the 3 agents. In conclusion, the binding properties of adalimumab, infliximab, and etanercept were similar for soluble TNF, and very similar for mTNF, yet none of the 3 was able to induce CDC in activated PBMC. These results suggest that the different clinical efficacy profiles of these agents are not explained by differences in either TNF-intrinsic binding properties or complement lysis.